Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
Record guidance disappoints, so talk once again turns to deals.
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.